Fujian Haixi Pharmaceuticals Co Ltd
Company Profile
Business description
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
Contact
No. 177 Jinda Road
Floor 3rd & 4th, Block B
Jianxin Town
Cangshan District,Fujian Province
Fuzhou350028
CHNT: +86 59187519936
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
203
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
stocks
Fair value upgrade for this ASX income player
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.60 | 59.90 | 0.68% |
| CAC 40 | 7,961.80 | 144.86 | 1.85% |
| DAX 40 | 23,190.98 | 510.94 | 2.25% |
| Dow JONES (US) | 46,341.51 | 1,125.37 | 2.49% |
| FTSE 100 | 10,369.23 | 192.78 | 1.89% |
| HKSE | 25,294.03 | 505.89 | 2.04% |
| NASDAQ | 21,590.63 | 795.99 | 3.83% |
| Nikkei 225 | 53,739.68 | 2,675.96 | 5.24% |
| NZX 50 Index | 12,825.87 | 86.24 | -0.67% |
| S&P 500 | 6,528.52 | 184.80 | 2.91% |
| S&P/ASX 200 | 8,671.80 | 53.10 | 0.62% |
| SSE Composite Index | 3,948.55 | 56.69 | 1.46% |